General Information of Drug Combination (ID: DC22S8F)

Drug Combination Name
Amonafide Vinflunine
Indication
Disease Entry Status REF
Astrocytoma Investigative [1]
Component Drugs Amonafide   DMAH59S Vinflunine   DMTJAEP
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: U251
Zero Interaction Potency (ZIP) Score: 1.55
Bliss Independence Score: 0.76
Loewe Additivity Score: 1.81
LHighest Single Agent (HSA) Score: 3.73

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adenocarcinoma DC5U0PX HCT-15 Investigative [1]
Adult acute myeloid leukemia DCNFACN HL-60(TB) Investigative [1]
Adult T acute lymphoblastic leukemia DCVMZH2 MOLT-4 Investigative [1]
Anaplastic large cell lymphoma DC0YH00 SR Investigative [1]
Large cell lung carcinoma DCB9O8K NCI-H460 Investigative [1]
Non-small cell lung carcinoma DCSPR9B HOP-92 Investigative [1]
Carcinoma DCRE1YA MCF7 Investigative [4]
Invasive ductal carcinoma DCIG1BM HS 578T Investigative [4]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DrugCom(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 ClinicalTrials.gov (NCT00715637) Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDEStudy. U.S. National Institutes of Health.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.